Phio Pharmaceuticals Q3 2026 earnings
R&D spending surged 159% YoY to $3.1M as the company completed commercial-scale manufacturing and submitted Phase 1b data to the FDA, extending cash runway into 2027.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| EPS (GAAP) | -$0.36 | +18% | +0.0% | Ex. 99.1, income statement |
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin not stated in the 8-K
- Operating expenses $4.27M (+70% YoY)
- One-offs in the quarter not stated in the 8-K
- Effective tax rate not stated in the 8-K
- Non-GAAP bridge No non-GAAP reconciliation provided.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash runway | Second half of 2027 | Second half of 2027 | — | — |
| Shares outstanding | 11.95M | 11.62M | 5.47M | +2.8% QoQ, +119% YoY |
Guidance
not stated in the 8-K
What drove it
- Revenue story No revenue reported.
- EPS story Net loss widened due to higher R&D expenses; EPS improved YoY due to a higher share count.
- One-off check not stated in the 8-K
The good
- Completed commercial-scale cGMP manufacturing of PH-762 drug substance.
- Submitted Phase 1b clinical study report and briefing documents to FDA.
The bad
- R&D expenses increased 159% YoY driven by nonclinical toxicology, drug substance, and clinical supplies costs.
- Cash and cash equivalents declined 18% QoQ to $10.6M.
The ugly
- none
Open questions
- When will the FDA respond to the November 2026 submission?
- What is the specific timeline for initiating the Phase 2b study?
- What is the exact amount of the ATM program proceeds used?
Full release
Phio Pharmaceuticals (PHIO) earnings release, November 5, 2026
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study Initiation
PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory Documents to FDA
KING OF PRUSSIA, PA, November 5, 2026 (NEWSFILE) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics using its proprietary INTASYL® gene-silencing technology to eliminate cancer, today reported financial results for the quarter ended September 30, 2026, and provided a business update.
“We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study initiation,” said Robert J. Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals. “Commercial-scale drug substance manufacturing was completed and shipped to our drug product manufacturer in preparation for making clinical trial supply material. We have submitted detailed information to FDA providing final analysis of our Phase 1b clinical trial and the fundamentals of our intended upcoming Phase 2b study.”
PH-762 Development Update
PH-762 was evaluated in a U.S. multicenter Phase 1b dose-escalation clinical trial assessing intratumoral administration in patients with cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. The study (NCT 06014086) was designed to evaluate the safety and tolerability of neoadjuvant treatment with PH-762, assess tumor response, and identify a dose or dose range for further clinical development. The study enrolled 22 patients, consisting of 20 patients with cutaneous squamous cell carcinoma, one patient with melanoma, and one patient with Merkel cell carcinoma.
The clinical trial was completed in June 2026, and the final clinical study report was submitted to FDA with a meeting request and briefing document outlining the nonclinical and clinical pharmacology programs, scientific rationale for continued development, completed Phase 1b results, and details of the planned Phase 2b neoadjuvant study in cSCC. The submission seeks FDA feedback on the proposed development strategy and next steps, with a response expected from the FDA by the end of November 2026.
The Company also announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing an important CMC (chemistry, manufacturing and controls) milestone that supports the planned Phase 2b clinical program, which is expected to be initiated in the first quarter of 2027.
Scientific and Corporate Activities
During the quarter, the Company presented PH-762 Phase 1b clinical trial data at scientific and investor conferences and roadshows. These included the Life Sciences Future Conference, King of Prussia, PA, H.C. Wainwright Conference, NYC, NIBA 153 rd
Conference, Fort Lauderdale, FL, Life Sciences Virtual Investor Conference, and Renmark Financial Virtual Non-Deal Roadshows.
The Company further strengthened its intellectual property position through multiple patent-related achievements during the quarter. Phio’s patent portfolio currently includes 56 issued patents and 34 pending applications worldwide, providing broad protection for its INTASYL® self-delivering RNAi therapeutic platform and product candidates through at least 2038, with additional pending applications extending potential protection into 2044.
Financial Results
Cash Position
As of September 30, 2026, we had cash and cash equivalents of $10.6 million as compared with $21.0 million at December 31, 2025. The Company continues to focus its resources on advancing PH-762 while prudently managing general and administrative expenses.
Research and Development Expenses
Research and development expenses for the three months ended September 30, 2026 were $3.0 million, an increase of $1.9 million or 159%, compared with the three months ended September 30, 2025. The increase was primarily driven by a $1.5 million increase in nonclinical toxicology study costs, drug substance costs and clinical supplies costs as compared to the clinical study costs that occurred during the prior year period, and a $0.3 million increase in other development related costs.
Research and development expenses for the nine months ended September 30, 2026 were $8.9 million, an increase of $5.8 million or 180% as compared with the nine months ended September 30, 2025. The increase in research and development expenses was primarily driven by a $4.5 million increase in nonclinical toxicology study costs, drug substance costs and clinical supplies costs, all of which were associated with advancing the PH-762 program. In addition, research and development expenses increased by approximately $0.3 million related to employee headcount costs, $0.6 million related to outside services and consultants and $0.2 million related to patent activity.
Management believes that research and development expenses will continue to increase as we advance our PH-762 program.
General and Administrative Expenses
General and administrative expenses for the three months ended September 30, 2026 were $1.2 million, a decrease of $100 thousand or 9%, compared with the three months ended September 30, 2025. This decrease was primarily driven by a reduction in outsourced consulting services.... (truncated)ices and consultant expenses as compared to the prior year period.
Net Loss
Net loss was $4.2 million for the three months ended September 30, 2026 as compared with $2.4 million for the three months ended September 30, 2025. The increase in net loss was attributable to higher research and development expenses associated with advancing the PH-762 program.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio’s INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company’s website, www.phiopharma.com.
Forward Looking Statements
Financial statements
Income Statement
Three Months Ended — (Unaudited) (in thousands)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 3,062 | 1,181 | 8,936 | 3,141 |
| General and administrative | 1,206 | 1,324 | 3,767 | 3,545 |
| Total operating expenses | 4,268 | 2,505 | 12,703 | 6,686 |
| Operating loss | -4,268 | -2,505 | -12,703 | -6,686 |
| Interest income, net | 105 | 113 | 395 | 357 |
| Other income, net | 3 | 7 | 2 | |
| Net loss | -4,160 | -2,392 | -12,301 | -6,327 |
| Basic and diluted | -0.36 | -0.44 | -1.06 | -1.3 |
| Weighted average number of common shares outstanding | ||||
| Basic and diluted | 11,689,942 | 5,468,584 | 11,641,747 | 4,859,134 |
Balance Sheet
September 30, — (Unaudited) (in thousands)
| September 30, – 2026 | December 31, – 2025 | |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 10,609 | 21,031 |
| Prepaid expenses and other current assets | 701 | 445 |
| Total current assets | 11,310 | 21,476 |
| Property and equipment, net | 7 | 11 |
| Total assets | 11,317 | 21,487 |
| Current liabilities: | ||
| Accounts payable | 886 | 435 |
| Accrued expenses | 1,811 | 905 |
| Total liabilities | 2,697 | 1,340 |
| Stockholders' equity: | ||
| Common stock, $0.0001 par value, 100,000,000 shares authorized; 11,951,632 and 11,617,250 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid-in capital | 175,974 | 175,200 |
| Accumulated deficit | -167,355 | -155,054 |
| Total stockholders' equity | 8,620 | 20,147 |
| Total liabilities and stockholders' equity | 11,317 | 21,487 |
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the possibility that our INTASYL® siRNA gene silencing technology will make the body’ s immune cells more effective in killing cancer cells, the potential for PH-762 to present a viable non-surgical alternative for skin cancer, our plans and expectations regarding FDA submissions and related interactions, including our expectation that the FDA will respond to our most recent submission in November 2026, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, our belief that the release of our first commercial scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient) validates our supply chain readiness, supports our clinical development and potential commercialization strategy for PH-762, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, expectations regarding our intellectual property position, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs